title: Is there a need to add another dimension (time) to the evaluation of the arrhythmogenic potential of new drug candidates in vitro?
authors.affiliation: From GlaxoSmithKline, Research Triangle Park, NC. claire.y.townsend@gsk.com.
authors.forename: Claire
authors.initials: C
authors.lastname: Townsend
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005260:Female; D006801:Humans; D062554:NAV1.5 Voltage-Gated Sodium Channel / Q000187:drug effects* / Q000502:physiology*; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D016171:Torsades de Pointes / Q000453:epidemiology*
chemical_list: D062554:NAV1.5 Voltage-Gated Sodium Channel; D026902:Potassium Channel Blockers; C568321:Scn5a protein, mouse
keywords: Editorials; arrhythmias, cardiac; phosphatidylinositol 3-kinase; safety; sodium channels